![](/images/graphics-bg.png)
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or RelapsedRefractory Acute Myeloid Leukemia Ineligible for Intensive Therapy
المؤلفون المشاركون
Sarlo, Chiara
Ottaviani, Licia
Buccisano, Francesco
Ditto, Concetta
De Santis, Giovanna
Del Principe, Maria Ilaria
Maurillo, Luca
Venditti, Adriano
Di Caprio, Luigi
Amadori, Sergio
Cefalo, Mariagiovanna
Nasso, Daniela
Di Veroli, Ambra
Grasso, Maria Assunta
Cicconi, Laura
المصدر
Leukemia Research and Treatment
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-04-28
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
We explored the safety and efficacy of bortezomib given as single agent in patients with untreated or relapsed/refractory acute myeloid leukemia (AML), unfit for conventional chemotherapy.
Fourteen patients were treated with bortezomib 1.5 mg/m2 administered twice weekly for two weeks, every 3 weeks.
Median age was 70 years (range 60–81) and the median number of cycles delivered was 2 (range 1–4).
Of 13 evaluable patients, in 8 (61%), the administration of bortezomib resulted in an antileukemic effect as demonstrated by peripheral blood and/or bone marrow blast reduction.
In 4 (50%) of these 8, a decrease by 37% of transfusion requirement was also observed (P = 0.009).
Overall median survival was 4 months (range 0.25–10).
Neurotoxicity was the most frequent adverse event with 7 of 13 (54%) patients experiencing grades 3-4 peripheral neuropathy.
Neurotoxicity led to treatment discontinuation in 4 (57%) of 7.
In conclusion, the observed anti-leukemic activity of bortezomib indicates that there is room for designing additional studies in which combination with other chemotherapeutic agents should be considered.
Clinical registration no.: EUDRACT 2006-006923-38.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Sarlo, Chiara& Buccisano, Francesco& Maurillo, Luca& Cefalo, Mariagiovanna& Di Caprio, Luigi& Cicconi, Laura…[et al.]. 2013. Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or RelapsedRefractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leukemia Research and Treatment،Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-492032
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Sarlo, Chiara…[et al.]. Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or RelapsedRefractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leukemia Research and Treatment No. 2013 (2013), pp.1-6.
https://search.emarefa.net/detail/BIM-492032
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Sarlo, Chiara& Buccisano, Francesco& Maurillo, Luca& Cefalo, Mariagiovanna& Di Caprio, Luigi& Cicconi, Laura…[et al.]. Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or RelapsedRefractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leukemia Research and Treatment. 2013. Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-492032
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-492032
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)